-
Nanoform successfully completes new share issue raising EUR 25 million to prepare for GMP manufacturing in the USA
-
-
Global experts in nanotechnology and drug particle engineering
Our latest videos
Press releases
-
Regulatory June 13, 2022Nanoform Chief of Business Operations Gonçalo Andrade steps down
-
Regulatory June 13, 2022Nanoform Finland Plc – Manager’s transactions – Albert Hæggström
-
Regulatory June 13, 2022Nanoform Finland Plc – Manager’s transactions – Miguel Calado
Nanoform published its Interim Report January-March 2022 on May 24th, 2022, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time.
a
About Nanoform
Our work enables our partners to overcome drug development challenges to rapidly progress novel drugs to market. We are driven by a passion for innovation, and constantly work to find ground-breaking solutions that enhance drug effectiveness and targeting.
Expert services
Our nanoforming services provide solutions to complex formulation challenges by increasing drug solubility and bioavailability. The advanced production of nanoparticles provides pharmacokinetic improvements, commercial opportunities and novel avenues for drug delivery.
Team
We have established a multidisciplinary team that brings together world-class scientists with experts in pharmaceutical business development. Every member of the team is committed to the enhancement of drug compounds for swift progression to the market.
Working together for enhanced drug development
Our nanoforming technologies and services span the full range of drug development from small-molecule nanoparticles to large-molecule biologics. We support all phases of drug development, accelerating your time to clinic for GMP manufacture while also increasing possibilities and probabilities of success in taking your product to market.
Nanoform’s platform is exciting for its broad applicability to drug development across all therapeutic areas
